CN103911306A - Lactobacillus gasseri strain and uses thereof - Google Patents
Lactobacillus gasseri strain and uses thereof Download PDFInfo
- Publication number
- CN103911306A CN103911306A CN201310002838.XA CN201310002838A CN103911306A CN 103911306 A CN103911306 A CN 103911306A CN 201310002838 A CN201310002838 A CN 201310002838A CN 103911306 A CN103911306 A CN 103911306A
- Authority
- CN
- China
- Prior art keywords
- vaginitis
- bacterial strain
- lactobacillus gasseri
- present
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 39
- 206010046914 Vaginal infection Diseases 0.000 claims abstract description 24
- 201000008100 Vaginitis Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 210000004392 genitalia Anatomy 0.000 claims abstract description 4
- 230000001580 bacterial effect Effects 0.000 claims description 55
- 241000222122 Candida albicans Species 0.000 claims description 21
- 241000191967 Staphylococcus aureus Species 0.000 claims description 21
- 229940095731 candida albicans Drugs 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 16
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 5
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 5
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 claims description 5
- 208000011833 infective vaginitis Diseases 0.000 claims description 5
- 230000005906 menstruation Effects 0.000 claims description 5
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 abstract description 8
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 210000002919 epithelial cell Anatomy 0.000 abstract description 6
- 230000008485 antagonism Effects 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 230000003042 antagnostic effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 244000005706 microflora Species 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a strain, which is a Lactobacillus gasseri strain and is characterized in that the preservation number is CGMCC No.6362. The present invention further provides uses of the strain in preparation of drugs for prevention and/or treatment of vaginitis, preparation of vagina care products, and preparation of external genitalia sanitary products. With the technical scheme, antagonism effects of the Lactobacillus gasseri strain on multiple pathogenic bacteria can be achieved. In addition, the strain has high adhesion to vaginal epithelial cells. The strain can well meet practical clinical application requirements.
Description
Technical field
The present invention relates to medical microbial technology field, particularly, relate to a kind of purposes of bacterial strain and this bacterial strain of Lactobacillus gasseri.
Background technology
In healthy women vagina, exist some dominant microfloras, these dominant microfloras play a part crucial to maintaining the balance of vagina normal microflora.Dominant microflora plays by materials such as secretion lactic acid, hydrogen peroxide, bacteriocins the effect of killing pathogenic bacterium.Meanwhile, play the effect of biological barrier at the epithelial competition adhesion of vaginal mucosa, stoped the breeding of pathogenic bacterium at vagina.
But many reasons such as antibiotic use, bad health habit, environment, chemicotherapy, stress can be destroyed vagina normal microflora balance, dominant microflora quantity is reduced, pathogenic bacterium amount reproduction, and cause various vaginopathys as bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, child's property vaginitis, menstruation vaginitis, senile vaginitis, mixed infective vaginitis etc.
Recover Lactobacillus vaginalis advantage by the intervention of external source bacterium, thereby the equilibrium state that reaches normal vaginal microbial flora is a kind of effective means that prevents and/or treats colpitis.But, known external source bacterium to the antagonistic action of pathogenic bacterium still a little less than, be difficult to meet actual clinical application demand.
Summary of the invention
The object of this invention is to provide a kind of external source bacteria strain stronger to the antagonistic action of pathogenic bacterium, this bacterial strain can meet actual clinical application demand preferably.
To achieve these goals, the present inventor separates and has obtained a strain Bacterium lacticum from volunteer's vagina, finds that unexpectedly this lactobacterium strain has the stronger antagonistic action to pathogenic bacterium, has obtained the present invention thus.
On the one hand, the invention provides a kind of bacterial strain, this bacterial strain is the bacterial strain of Lactobacillus gasseri (Lactobacillus gasseri), it is characterized in that, the preserving number of this bacterial strain is CGMCC No.6362.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes for the preparation of in the colpitic medicine of prevention.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes for the preparation of in the colpitic medicine for the treatment of.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes of preparing in vaginal care articles for use.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes of preparing in genitalia sanitary product.
By technique scheme, the present invention can realize the antagonistic action to various pathogens effectively.In addition, bacterial strain of the present invention also has the higher adhesive capacity to vaginal epithelial cell and higher lactic acid producing ability.Thereby bacterial strain of the present invention can meet actual clinical application demand preferably.
Other features and advantages of the present invention are described in detail the embodiment part subsequently.
Biological preservation
Lactobacillus gasseri of the present invention (Lactobacillus gasseri) bacterial strain, be deposited in (address: No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, China Committee for Culture Collection of Microorganisms's common micro-organisms center on July 17th, 2012, Institute of Microorganism, Academia Sinica, postcode: 100101) (depositary institution be abbreviated as CGMCC), deposit number is CGMCC No.6362.
Embodiment
Below the specific embodiment of the present invention is elaborated.Should be understood that, embodiment described herein only, for description and interpretation the present invention, is not limited to the present invention.
On the one hand, the invention provides a kind of bacterial strain, this bacterial strain is the bacterial strain of Lactobacillus gasseri (Lactobacillus gasseri), it is characterized in that, the preserving number of this bacterial strain is CGMCC No.6362.
Wherein, this bacterial strain has the 16S rDNA sequence shown in SEQ ID NO:1.16S rDNA sequence is the DNA sequence dna of coding 16S rRNA, in the classification of bacterial strain and/or identify to have important reference value.
Wherein, the colonial morphology of this bacterial strain on MRS solid medium is circular bacterium colony, diameter 0.5-0.75mm, and surface irregularity, is Gram-positive tyrothricin under the microscope.
Wherein, the culture condition of this bacterial strain can adopt the cultural method of known Lactobacillus gasseri, for example, this bacterial strain can be on MRS liquid nutrient medium and MRS solid medium normal growth.Wherein, the growth temperature of this bacterial strain can be conventional temperature, and for example, growth temperature can be 36-38 ℃.
In the present invention, MRS liquid nutrient medium refers to by the tween-80 of the ammonium citrate of the sodium acetate of the glucose of the extractum carnis of the yeast extract paste of the peptone of 10g, 5g, 10g, 20g, 5g, 2g, 1mL, the MgSO of 0.58g
47H
2the MnSO of O, 0.25g
44H
2the K of O, 2g
2hPO
4mix with the distilled water of 1000mL, regulating pH value is 6.2-6.4 and the substratum that obtains after 121 ℃ of high pressure steam sterilizations.
In the present invention, MRS solid medium refers to by the tween-80 of the ammonium citrate of the sodium acetate of the glucose of the extractum carnis of the yeast extract paste of the peptone of 10g, 5g, 10g, 20g, 5g, 2g, 1mL, the MgSO of 0.58g
47H
2the MnSO of O, 0.25g
44H
2the K of O, 2g
2hPO
4, the agar powder of 20g and the distilled water of 1000mL mixes, regulating pH value is 6.2-6.4 and the substratum that obtains after 121 ℃ of high pressure steam sterilizations.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes for the preparation of in the colpitic medicine of prevention.
Wherein, described vaginitis can be at least one in bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, child's property vaginitis, menstruation vaginitis, senile vaginitis and mixed infective vaginitis.
Wherein, described vaginitis can be the vaginitis of at least one initiation in Candida albicans (Candida albicans), intestinal bacteria (Escherichia coli) and streptococcus aureus (Staphylococcus aureus).
Wherein, above-mentioned bacterial strains can bring into play in the following way prevention colpitic effect: (1) inoculates above-mentioned bacterial strains in MRS liquid nutrient medium, and cultivate for cell concentration be 10
7individual thalline/every mL, obtains the nutrient solution of above-mentioned bacterial strains; (2) dip above-mentioned nutrient solution with Sterilized sanitation cotton balls, wiping vagina, uses the nutrient solution of 3-10mL at every day 1-2 time at every turn., the nutrient solution of above-mentioned bacterial strains can be used as for preventing colpitic medicine.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes for the preparation of in the colpitic medicine for the treatment of.
Wherein, described vaginitis is at least one in bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, child's property vaginitis, menstruation vaginitis, senile vaginitis and mixed infective vaginitis.
Wherein, described vaginitis can be the vaginitis of at least one initiation in Candida albicans (Candida albicans), intestinal bacteria (Escherichia coli) and streptococcus aureus (Staphylococcus aureus).
Wherein, above-mentioned bacterial strains can bring into play in the following way treatment colpitic effect: (1) inoculates above-mentioned bacterial strains in MRS liquid nutrient medium, and cultivate for cell concentration be 10
7individual thalline/every mL, obtains the nutrient solution of above-mentioned bacterial strains; (2) dip above-mentioned nutrient solution with Sterilized sanitation cotton balls, wiping vagina, uses the nutrient solution of 3-10mL at every day 1-2 time at every turn., the nutrient solution of above-mentioned bacterial strains can be used as and is used for the treatment of colpitic medicine.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes of preparing in vaginal care articles for use.
On the other hand, the present invention also provides above-mentioned bacterial strains in the purposes of preparing in genitalia sanitary product.
Below will describe the present invention by embodiment.
Test implementation example 1
According to the document (foundation of the sequence measurement of polluted bacteria in 16S rDNA Rapid identification blood products, Ying Yanling etc., China's microbiology and Journal of Immunology, 10 phases in 2009) in method, the sequence of 16S rDNA to Lactobacillus gasseri bacterial strain CGMCC No.6362 of the present invention checks order, and sequencing result confirms that Lactobacillus gasseri bacterial strain of the present invention is had to the 16S rDNA sequence shown in SEQ ID NO:1.
Embodiment 1
The present embodiment is used for illustrating the antagonistic action of bacterial strain of the present invention to Candida albicans (Candida albicans).In the present embodiment, Candida albicans used is the bacterial strain that is 10231 purchased from the article number of ATCC.
It is cell concentration 1 × 10 that Lactobacillus gasseri CGMCC No.6362 is cultivated with MRS liquid nutrient medium
7the nutrient solution of CFU/mL, called after nutrient solution A.
It is cell concentration 1 × 10 that Candida albicans (Candida albicans) is cultivated with MRS liquid nutrient medium
7the nutrient solution of CFU/mL, called after nutrient solution B.
Above-mentioned nutrient solution A and above-mentioned nutrient solution B equal-volume are mixed as experimental group, by independent above-mentioned nutrient solution B as a control group.
By the experimental group of 1mL and control group nutrient solution, be inoculated in the MRS liquid nutrient medium of 150mL respectively, cultivate 24 hours at 37 ℃, obtain the nutrient solution of common cultivation.
Get respectively the common cultivation nutrient solution 100 μ L of experimental group and control group, be inoculated into (Sabouraud's dextrose agar substratum in 15mL Candida albicans selective medium flat board, purchased from Qingdao high-tech park Hai Bo Bioisystech Co., Ltd, article No.: HB0235-5) in, at 37 ℃, select to cultivate 24 hours, then Candida albicans is counted.
Count results demonstration, the Candida albicans cell concentration of experimental group is only 7.41 × 10
5cFU/mL, and the Candida albicans cell concentration of control group is up to 4.67 × 10
6cFU/mL.
Comparative example 1
Method according to embodiment 1 is tested, different, by the Lactobacillus gasseri that to replace with respectively purchased from the article number of ATCC be 9857 of the Lactobacillus gasseri CGMCC No.6362 in embodiment 1.
Count results shows, the Lactobacillus gasseri that is 9857 for the article number purchased from ATCC, and the Candida albicans cell concentration of experimental group has also reached 2.14 × 10
6cFU/mL, and the Candida albicans cell concentration of control group is still 4.67 × 10
6cFU/mL.
Embodiment 2
The present embodiment is used for illustrating the antagonistic action of bacterial strain of the present invention to intestinal bacteria (Escherichia coli).In the present embodiment, intestinal bacteria used are the bacterial strain that is 35218 purchased from the article number of ATCC.
It is cell concentration 1 × 10 that Lactobacillus gasseri CGMCC No.6362 is cultivated with MRS liquid nutrient medium
7the nutrient solution of CFU/mL, called after nutrient solution A.
It is cell concentration 1 × 10 that intestinal bacteria (Escherichia coli) are cultivated with MRS liquid nutrient medium
7the nutrient solution of CFU/mL, called after nutrient solution B.
Above-mentioned nutrient solution A and above-mentioned nutrient solution B equal-volume are mixed as experimental group, by independent above-mentioned nutrient solution B as a control group.
By the experimental group of 1mL and control group nutrient solution, be inoculated in the MRS liquid nutrient medium of 150mL respectively, cultivate 24 hours at 37 ℃, obtain the nutrient solution of common cultivation.
Get respectively the common cultivation nutrient solution 100 μ L of experimental group and control group, be inoculated into (eosin methylene blue nutrient agar in 15mL intestinal bacteria selective medium flat board, purchased from Qingdao high-tech park Hai Bo Bioisystech Co., Ltd, article No.: HB7010) in, at 37 ℃, select to cultivate 24 hours, then intestinal bacteria are counted.
Count results demonstration, the coli somatic concentration of experimental group is only 4.17 × 10
7cFU/mL, and the coli somatic concentration of control group is up to 2.04 × 10
8cFU/mL.
Comparative example 2
Method according to embodiment 2 is tested, different, by the Lactobacillus gasseri that to replace with respectively purchased from the article number of ATCC be 9857 of the Lactobacillus gasseri CGMCC No.6362 in embodiment 1.
Count results shows, the Lactobacillus gasseri that is 9857 for the article number purchased from ATCC, and the coli somatic concentration of experimental group has also reached 1.04 × 10
8cFU/mL, and the coli somatic concentration of control group is still 2.04 × 10
8cFU/mL.
Embodiment 3
The present embodiment is used for illustrating the antagonistic action of bacterial strain of the present invention to streptococcus aureus (Staphylococcus aureus).In the present embodiment, streptococcus aureus used is the bacterial strain that is 25923 purchased from the article number of ATCC.
It is cell concentration 1 × 10 that Lactobacillus gasseri CGMCC No.6362 is cultivated with MRS liquid nutrient medium
7the nutrient solution of CFU/mL, called after nutrient solution A.
It is cell concentration 1 × 10 that streptococcus aureus (Staphylococcus aureus) is cultivated with MRS liquid nutrient medium
7the nutrient solution of CFU/mL, called after nutrient solution B.
Above-mentioned nutrient solution A and above-mentioned nutrient solution B equal-volume are mixed as experimental group, by independent above-mentioned nutrient solution B as a control group.
By the experimental group of 1mL and control group nutrient solution, be inoculated in the MRS liquid nutrient medium of 150mL respectively, cultivate 24 hours at 37 ℃, obtain the nutrient solution of common cultivation.
Get respectively the common cultivation nutrient solution 100 μ L of experimental group and control group, be inoculated into (N.F,USP MANNITOL sodium-chlor nutrient agar on the streptococcus aureus selective medium flat board of 15L, purchased from Qingdao high-tech park Hai Bo Bioisystech Co., Ltd, article No.: HB4128-1) in, at 37 ℃, select to cultivate 24 hours, then streptococcus aureus is counted.
Count results demonstration, the streptococcus aureus cell concentration of experimental group is only 1.32 × 10
7cFU/mL, and the streptococcus aureus cell concentration of control group is up to 7.94 × 10
7cFU/mL.
Comparative example 3
Method according to embodiment 1 is tested, different, by the Lactobacillus gasseri that to replace with respectively purchased from the article number of ATCC be 9857 of the Lactobacillus gasseri CGMCC No.6362 in embodiment 1.
Count results shows, the Lactobacillus gasseri that is 9857 for the article number of ATCC, and the streptococcus aureus cell concentration of experimental group has also reached 3.54 × 10
7cFU/mL, and the streptococcus aureus cell concentration of control group is still 7.94 × 10
7cFU/mL.
Can find out according to the result of embodiment 1-3 and comparative example 1-3, Lactobacillus gasseri CGMCC No.6362 of the present invention has excellent antagonistic action to Candida albicans (Candida albicans), intestinal bacteria (Escherichia coli) and streptococcus aureus (Staphylococcus aureus).
Embodiment 4
The present embodiment is according to document (Wang Hongyan, Lactobacterium acidophilum is sticked and the research of Antagonism effect reproductive tract is epithelial, China microbiology and Journal of Immunology, the 24th the 10th phase of volume of October in 2004) in method measure the adhesive capacity of Lactobacillus gasseri CGMCC No.6362 of the present invention to vaginal epithelial cell.
After measured, Lactobacillus gasseri CGMCC No.6362 of the present invention is 15.32 ± 2.74 to the adhesion index of vaginal epithelial cell.
Comparative example 4
Measure according to the method for embodiment 4 Lactobacillus gasseri that is 9857 purchased from the article number of ATCC.
After measured, the Lactobacillus gasseri that is 9857 purchased from the article number of ATCC is 11.64 ± 1.47 to the adhesion index of vaginal epithelial cell.
Can find out according to the result of embodiment 4 and comparative example 4, Lactobacillus gasseri CGMCCNo.6362 of the present invention has the higher adhesive capacity to vaginal epithelial cell.
Embodiment 5
The present embodiment is according to document (Fan Yonghong, Wang Li, Liu Dan, etc. the study on determination method [J] of Rhizopus oryzae Lactic Acid from Fermentation Broth content. biotechnology, 2007,17(1): the method 54-55) is measured the lactic acid content of Lactobacillus gasseri CGMCC No.6362 of the present invention.
The lactic acid content of result Lactobacillus gasseri CGMCC of the present invention No.6362 is 6.7032g/L.
Comparative example 5
Measure the lactic acid content of the Lactobacillus gasseri that is 9857 purchased from the article number of ATCC according to the method for embodiment 5.
The lactic acid content of the Lactobacillus gasseri that is 9857 purchased from the article number of ATCC after measured, is 6.6683g/L.
Can find out according to the result of embodiment 5 and comparative example 5, Lactobacillus gasseri CGMCC No.6362 of the present invention has higher lactic acid producing ability.
More than describe the preferred embodiment of the present invention in detail; but the present invention is not limited to the detail in above-mentioned embodiment, within the scope of technical conceive of the present invention; can carry out multiple simple variant to technical scheme of the present invention, these simple variant all belong to protection scope of the present invention.
It should be noted that in addition, each concrete technical characterictic described in above-mentioned embodiment, in reconcilable situation, can combine by any suitable mode, for fear of unnecessary repetition, the present invention is to the explanation no longer separately of various possible array modes.
In addition, also can carry out arbitrary combination between various embodiment of the present invention, as long as it is without prejudice to thought of the present invention, it should be considered as content disclosed in this invention equally.
Claims (10)
1. a bacterial strain, this bacterial strain is the bacterial strain of Lactobacillus gasseri (Lactobacillus gasseri), it is characterized in that, the preserving number of this bacterial strain is CGMCC No.6362.
2. bacterial strain according to claim 1, wherein, this bacterial strain has the 16S rDNA sequence shown in SEQ ID NO:1.
3. the bacterial strain described in claim 1 or 2 is in the purposes for the preparation of in the colpitic medicine of prevention.
4. purposes according to claim 3, wherein, described vaginitis is at least one in bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, child's property vaginitis, menstruation vaginitis, senile vaginitis and mixed infective vaginitis.
5. purposes according to claim 3, wherein, described vaginitis is the vaginitis of at least one initiation in Candida albicans (Candida albicans), intestinal bacteria (Escherichia coli) and streptococcus aureus (Staphylococcus aureus).
6. the bacterial strain described in claim 1 or 2 is in the purposes for the preparation of in the colpitic medicine for the treatment of.
7. purposes according to claim 6, wherein, described vaginitis is at least one in bacterial vaginitis, monilial vaginitis, trichomonal vaginitis, child's property vaginitis, menstruation vaginitis, senile vaginitis and mixed infective vaginitis.
8. purposes according to claim 6, wherein, described vaginitis is the vaginitis of at least one initiation in Candida albicans (Candida albicans), intestinal bacteria (Escherichia coli) and streptococcus aureus (Staphylococcus aureus).
9. the bacterial strain described in claim 1 or 2 is in the purposes of preparing in vaginal care articles for use.
10. the bacterial strain described in claim 1 or 2 is in the purposes of preparing in genitalia sanitary product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310002838.XA CN103911306B (en) | 2013-01-05 | 2013-01-05 | Lactobacillus gasseri bacterial strain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310002838.XA CN103911306B (en) | 2013-01-05 | 2013-01-05 | Lactobacillus gasseri bacterial strain and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103911306A true CN103911306A (en) | 2014-07-09 |
| CN103911306B CN103911306B (en) | 2016-08-24 |
Family
ID=51037314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310002838.XA Active CN103911306B (en) | 2013-01-05 | 2013-01-05 | Lactobacillus gasseri bacterial strain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103911306B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106957811A (en) * | 2017-05-22 | 2017-07-18 | 泰安大凡神农制药有限公司 | Application of the form lactobacillus with bacteriostasis with Chinese medicine compound prescription and its in treatment gynaecological imflammation |
| CN108004187A (en) * | 2018-01-11 | 2018-05-08 | 广东龙创基药业有限公司 | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines |
| CN109402002A (en) * | 2018-11-01 | 2019-03-01 | 南京工业大学 | A kind of Lactobacillus gasseri and its application in preparation prevention premature labor drug |
| CN109983115A (en) * | 2016-12-20 | 2019-07-05 | 深圳华大生命科学研究院 | A kind of Lactobacillus gasseri and its cultural method and application |
| CN110831610A (en) * | 2017-07-07 | 2020-02-21 | 奥赛尔股份有限公司 | Use of vaginal lactobacillus for improving success rate of in vitro fertilization |
| WO2022100633A1 (en) * | 2020-11-10 | 2022-05-19 | 深圳华大生命科学研究院 | Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases |
| KR102554125B1 (en) * | 2022-10-24 | 2023-07-13 | (주)헥토헬스케어 | Lactobacillus gasseri BELG08 preventive or ameliorating effect on vaginitis and composition comprising the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1556852A (en) * | 2001-09-20 | 2004-12-22 | �����ɷ� | Lactic acid producing bacteria for use as probiotic organisms in the human vagina |
| WO2006045347A1 (en) * | 2004-10-22 | 2006-05-04 | Medinova Ag | Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens |
| CN1888051A (en) * | 2005-06-28 | 2007-01-03 | 北京天佑达生物工程科技有限公司 | Plant lactobacillus strain and its application |
-
2013
- 2013-01-05 CN CN201310002838.XA patent/CN103911306B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1556852A (en) * | 2001-09-20 | 2004-12-22 | �����ɷ� | Lactic acid producing bacteria for use as probiotic organisms in the human vagina |
| WO2006045347A1 (en) * | 2004-10-22 | 2006-05-04 | Medinova Ag | Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens |
| CN1888051A (en) * | 2005-06-28 | 2007-01-03 | 北京天佑达生物工程科技有限公司 | Plant lactobacillus strain and its application |
Non-Patent Citations (2)
| Title |
|---|
| SOLEDAD BORIS 等: "Role played by lactobacilli in controlling the", 《MICROBES AND INFECTION》, 30 April 2004 (2004-04-30) * |
| 余瑛 等: "不同乳杆菌对常见病原菌的抑菌效果研究", 《西南农业学报》, 7 June 2006 (2006-06-07) * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109983115A (en) * | 2016-12-20 | 2019-07-05 | 深圳华大生命科学研究院 | A kind of Lactobacillus gasseri and its cultural method and application |
| CN106957811A (en) * | 2017-05-22 | 2017-07-18 | 泰安大凡神农制药有限公司 | Application of the form lactobacillus with bacteriostasis with Chinese medicine compound prescription and its in treatment gynaecological imflammation |
| CN106957811B (en) * | 2017-05-22 | 2019-11-26 | 山东神农医院管理有限公司 | Format lactobacillus and Chinese medicine compound prescription with bacteriostasis and its application in treatment gynaecological imflammation |
| CN110831610A (en) * | 2017-07-07 | 2020-02-21 | 奥赛尔股份有限公司 | Use of vaginal lactobacillus for improving success rate of in vitro fertilization |
| CN108004187A (en) * | 2018-01-11 | 2018-05-08 | 广东龙创基药业有限公司 | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines |
| CN108004187B (en) * | 2018-01-11 | 2020-03-10 | 广东龙创基药业有限公司 | Lactobacillus gasseri and application thereof in preparing vagina bacteriostatic drug |
| CN109402002A (en) * | 2018-11-01 | 2019-03-01 | 南京工业大学 | A kind of Lactobacillus gasseri and its application in preparation prevention premature labor drug |
| WO2022100633A1 (en) * | 2020-11-10 | 2022-05-19 | 深圳华大生命科学研究院 | Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases |
| KR102554125B1 (en) * | 2022-10-24 | 2023-07-13 | (주)헥토헬스케어 | Lactobacillus gasseri BELG08 preventive or ameliorating effect on vaginitis and composition comprising the same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103911306B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103911305B (en) | Lactobacillus crispatus bacterial strain and uses thereof | |
| CN103911306A (en) | Lactobacillus gasseri strain and uses thereof | |
| Mortazavian et al. | Effects of dry matter standardization order on biochemical and microbiological characteristics of freshly made probiotic doogh (Iranian fermented milk drink). | |
| CN102690771B (en) | Functional lactobacillus plantarum and application thereof | |
| CN102206599B (en) | Oxygen-resistant acid-resistant Bifidobacterium longum | |
| CN103911308A (en) | Lactobacillus crispatus strain and its uses | |
| CN103540545B (en) | Pediococcus pentosaceus and application thereof | |
| CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
| CN102747009A (en) | Lactobacillus plantarum PY-1 and use method of lactobacillus plantarum PY 1 in fermentation of dairy products | |
| KR101720145B1 (en) | Cosmetic composition for prevention and improvement of vaginosis | |
| CN103911309A (en) | Lactobacillus gasseri strain and its uses | |
| CN103275893A (en) | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants | |
| US11492588B2 (en) | Lactococcus lactis subsp. lactis CCFM1018 and application thereof in preparation of food and medicine for excreting plasticizer | |
| CN104140937A (en) | Lactobacillus plantarum KLDS1001 and application of lactobacillus plantarum KLDS1001 to inhibition of streptococcus mutans | |
| CN110819569A (en) | Lactobacillus salivarius LS97 and application thereof | |
| CN109481476A (en) | Application of the lactobacillus fermenti CQPC04 in the food or drug that preparation improves ulcerative colitis | |
| CN109182165A (en) | One plant of Lactobacillus helveticus and its application during bee raising | |
| CN103911307B (en) | Lactobacillus crispatus bacterial strain and uses thereof | |
| CN103409334A (en) | Lactobacillus for inhibiting pathogenic bacteria of vaginitis and application thereof | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN114480214A (en) | Lactobacillus paracasei separated from Tibet Aliyak milk keloid and application thereof | |
| CN104232537A (en) | Lactobacillus crispatus and application thereof | |
| CN103555604B (en) | Lactobacillus salivarius capable of inhibiting Candida albicans growth, and separation method thereof | |
| CN109362882A (en) | Lactobacillus fermenti CQPC07 and its application in the food or drug that preparation improves ulcerative colitis | |
| Njoki et al. | Probiotic potential of lactic acid bacteria isolated from coconut (Cocos Nucifera) wine (mnazi) in Kenya |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210909 Address after: 300451 s1316, 13th floor, experimental building, Tianjin International Biological Research Institute, No. 220, Dongting Road, Tianjin Development Zone, Binhai New Area, Tianjin Patentee after: XINLIFEI BIOMEDICAL TECHNOLOGY (TIANJIN) Co.,Ltd. Patentee after: Zhejiang xinlifei Biotechnology Co.,Ltd. Address before: 300457 s1316, 13th floor, experimental building, Tianjin International Biological Research Institute, No. 220, Dongting Road, development zone, Binhai New Area, Tianjin Patentee before: XINLIFEI BIOMEDICAL TECHNOLOGY (TIANJIN) Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231025 Address after: Room 707, 7th Floor, No. 48 Zijinghua Road (East Building), Xihu District, Hangzhou City, Zhejiang Province, 310000 Patentee after: Zhejiang xinlifei Biotechnology Co.,Ltd. Address before: 300451 s1316, 13th floor, experimental building, Tianjin International Biological Research Institute, No. 220, Dongting Road, Tianjin Development Zone, Binhai New Area, Tianjin Patentee before: XINLIFEI BIOMEDICAL TECHNOLOGY (TIANJIN) CO.,LTD. Patentee before: Zhejiang xinlifei Biotechnology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231211 Address after: Room 206, 2nd Floor, Building 5, No. 368 Jinpeng Street, Sandun Town, Xihu District, Hangzhou City, Zhejiang Province, 310000 Patentee after: HANGZHOU HELI XINJIAN INDUSTRIAL Co.,Ltd. Address before: Room 707, 7th Floor, No. 48 Zijinghua Road (East Building), Xihu District, Hangzhou City, Zhejiang Province, 310000 Patentee before: Zhejiang xinlifei Biotechnology Co.,Ltd. |